[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”3.27.4″ z_index_tablet=”500″]

FANTASTIC NEWS! Study Published in JAMA Finds Treatment Extends Survival

In a spectacular development, a new study published in The Journal of the American Medical Association (JAMA) shows that treatment with lonafarnib extends lifespan in children with Progeria. This is the first evidence that lonafarnib alone improves survival for this fatal disease. On the heels of the JAMA study, PRF and Eiger BioPharmaceuticals announced they will partner to pursue FDA approval of lonafarnib so that children may access the drug with a prescription instead of through a clinical trial.

Read more by viewing the full PDF below.

[/et_pb_text][et_pb_button button_url=”https://www.progeriaresearch.org/wp-content/uploads/2018/09/17532-2018-NEWSLETTER_spreads_web-2.pdf” url_new_window=”on” button_text=”View the Full 2018 Newsletter” _builder_version=”3.21.1″ background_layout=”dark” z_index_tablet=”500″][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section]